Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Sanofi Ord Shs SNYNF

Healthcare

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood... see more

Add To Watchlist

Recent & Breaking News (OTCPK:SNYNF)

Anthrax And Government Contracts: PharmAthene And Altimmune Ahead Of Merger

Benzinga.com April 6, 2017

Sanofi Launches First-Ever ACT® Kids Toothpaste in the U.S.

PR Newswire April 3, 2017

Switching to Sanofi's Toujeo® Showed Significant Reductions in Blood Sugar and Significantly Lower Incidence of Hypoglycemia in a Real-World Observational Study

PR Newswire April 2, 2017

Watch These 8 Huge Put Purchases In Wednesday Trade

Benzinga.com March 29, 2017

Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT® (dupilumab) Approval

PR Newswire March 28, 2017

Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis

PR Newswire March 28, 2017

Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis

PR Newswire March 28, 2017

Keller Rohrback L.L.P. Files Class-Action Lawsuit Over the Inflated Price of Insulin

Business Wire March 25, 2017

Sanofi Genzyme Extends its Multiple Myeloma Journey Partners Program to Cities Nationwide to Help Improve Patient Outcomes through Peer-to-Peer Education

PR Newswire March 22, 2017

Sanofi Announces Results of First-of-Its-Kind Social Experiment Revealing Real-Life Impact of Symptoms on Allergy Sufferers in the U.S.

PR Newswire March 21, 2017

How These Drug Makers Stocks are Faring? -- Sanofi, Impax Laboratories, Heron Therapeutics, and GW Pharma

PR Newswire March 14, 2017

Sanofi and Voluntis Announce a Global Alliance to Deliver Digital Insulin Titration Solutions for People with Type 2 Diabetes

PR Newswire March 14, 2017

UK Patients Granted Early Access to Sanofi's Innovative Dermatology Treatment Dupilumab by MHRA

PR Newswire Europe Non Regulatory March 14, 2017

OilPrice.com: The Next Big Biotech Breakthrough Could Just be on the Horizon

PR Newswire March 13, 2017

Your Guide To Patent Play Exposure

Benzinga.com March 11, 2017

Regeneron and Sanofi to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions

PR Newswire March 7, 2017

Icahn's (Potential) Move Into Biotech

Benzinga.com March 4, 2017

Regeneron and Sanofi Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DUPIXENT® (dupilumab) in Moderate-to-Severe Atopic Dermatitis

PR Newswire March 4, 2017

Sanofi and Regeneron to Present New Data on Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses

PR Newswire February 27, 2017

Regeneron and Sanofi to Present New Data on DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses

PR Newswire February 27, 2017